These data demonstrate that RSL1D1 knockdown inhibits tumor growth both in a p53-dependent and -independent manner and p53 contributed to a major part of the efficacy in treating HCT116p53+/+ tumors (Fig. 8B and C). The gene discussed is RSL1D1; the disease is neoplasm.